Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics and Original Drugs Are Not the Same: Prof. Uchida
June 4, 2007
- SELF-MEDICATION NEWS IN BRIEF
June 4, 2007
- Mochida: Epadel, Atelec Drive Business
May 28, 2007
- Kissei: New Drugs Drive Business
May 28, 2007
- BUSINESS NEWS IN BRIEF
May 28, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming "Global Drug Discovery Company"
May 28, 2007
- Further Revision of Prescription Form Discussed at Chuikyo
May 28, 2007
- Korosho Proposes Increasing Generics' Share to 30% by FY2012
May 28, 2007
- JSMI General Assembly
May 28, 2007
- GENERICS NEWS IN BRIEF
May 28, 2007
- Baxter Focuses on BioScience, Med. Delivery, Renal Therapies: Mr Lema
May 28, 2007
- R&D NEWS IN BRIEF
May 28, 2007
- Top 4 Companies Show Strong Global Sales
May 28, 2007
- Relation between Tamiflu and Sleep to Be Investigated in Clinical Study
May 28, 2007
- Daiichi Sankyo: Growing Sales of Olmesartan Offset Declining Sales of Pravastatin
May 28, 2007
- MOF Questions Insurance Coverage of OTC-Like Drugs
May 28, 2007
- Astellas: Sales Up 4.7% to \920,624 Mil. with 48.9% Overseas
May 28, 2007
- REGULATORY NEWS IN BRIEF
May 28, 2007
- Eisai: Record-High Sales with Increases in Profits 7 Years in a Row
May 28, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 28, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…